Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Breast Cancer

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 108 articles: HTML format

Single Articles

November 2022
1. BARTELS SAL, Donker M, Poncet C, Sauve N, et al
   Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial.
   J Clin Oncol. 2022 Nov 16:JCO2201565. doi: 10.1200/JCO.22.01565.
   PubMed     Abstract available
   
   
   
2. HOFHEINZ RD, Merx K, Haag GM, Springfeld C, et al
   FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group.
   J Clin Oncol. 2022;40:3750-3761.
   PubMed     Abstract available
   
   
   
3. RUGO HS, Im SA, Cardoso F, Cortes J, et al
   Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.
   J Clin Oncol. 2022 Nov 4:JCO2102937. doi: 10.1200/JCO.21.02937.
   PubMed     Abstract available
   
   
   
4. MORAN MS, Ho AY
   Radiation Therapy for Low-Risk Breast Cancer: Whole, Partial, or None?
   J Clin Oncol. 2022 Nov 4:JCO2201751. doi: 10.1200/JCO.22.01751.
   PubMed     Abstract available
   
   
   
5. MCCAW ZR, Ludmir EB, Wei LJ
   Assessing the Clinical Utility of Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer.
   J Clin Oncol. 2022 Nov 3:JCO2201759. doi: 10.1200/JCO.22.01759.
   PubMed    
   
   
   
6. AKECHI T, Yamaguchi T, Uchida M, Imai F, et al
   Smartphone Psychotherapy Reduces Fear of Cancer Recurrence Among Breast Cancer Survivors: A Fully Decentralized Randomized Controlled Clinical Trial (J-SUPPORT 1703 Study).
   J Clin Oncol. 2022 Nov 2:JCO2200699. doi: 10.1200/JCO.22.00699.
   PubMed     Abstract available
   
   
   
7. HINDIE E, Groheux D
   Patient Selection for Internal Mammary Node Irradiation: Lymphoscintigraphy Can Help.
   J Clin Oncol. 2022;40:3669-3670.
   PubMed    
   
   
   
8. GAIL MH, Jatoi I
   Tools for Contralateral Prophylactic Mastectomy Decision Making.
   J Clin Oncol. 2022;40:3653-3659.
   PubMed     Abstract available
   
   
   October 2022
9. EVRON E, Ben-David MA, Kaidar-Person O, Corn BW, et al
   Nonsurgical Options for Risk Reduction of Contralateral Breast Cancer in BRCA Mutation Carriers With Early-Stage Breast Cancer.
   J Clin Oncol. 2022 Oct 28:JCO2201609. doi: 10.1200/JCO.22.01609.
   PubMed    
   
   
   
10. WONG FL, Lee JM, Leisenring WM, Neglia JP, et al
    Health Benefits and Cost-Effectiveness of Children's Oncology Group Breast Cancer Screening Guidelines for Chest-Irradiated Hodgkin Lymphoma Survivors.
    J Clin Oncol. 2022 Oct 20:JCO2200574. doi: 10.1200/JCO.22.00574.
    PubMed     Abstract available
    
    
    
11. SANCHEZ KG, Nangia JR, Schiff R, Rimawi MF, et al
    Elacestrant and the Promise of Oral SERDs.
    J Clin Oncol. 2022;40:3227-3229.
    PubMed    
    
    
    September 2022
12. CARROLL JE, Nakamura ZM, Small BJ, Zhou X, et al
    Elevated C-Reactive Protein and Subsequent Patient-Reported Cognitive Problems in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study.
    J Clin Oncol. 2022 Sep 30:JCO2200406. doi: 10.1200/JCO.22.00406.
    PubMed     Abstract available
    
    
    
13. JI J, Sun CL, Cohen HJ, Synold T, et al
    Inflammation and Clinical Decline After Adjuvant Chemotherapy in Older Adults With Breast Cancer: Results From the Hurria Older Patients Prospective Study.
    J Clin Oncol. 2022 Sep 20:JCO2201217. doi: 10.1200/JCO.22.01217.
    PubMed     Abstract available
    
    
    
14. LV M, Luo X, Chen Y
    Systematic Review on Electronic Health Interventions for Patients With Breast Cancer: Revisiting the Methodology.
    J Clin Oncol. 2022 Sep 19:JCO2201061. doi: 10.1200/JCO.22.01061.
    PubMed    
    
    
    
15. WHEELER SB, Rotter J, Gogate A, Reeder-Hayes KE, et al
    Cost-Effectiveness of Pharmacologic Treatment Options for Women With Endocrine-Refractory or Triple-Negative Metastatic Breast Cancer.
    J Clin Oncol. 2022 Sep 2:JCO2102473. doi: 10.1200/JCO.21.02473.
    PubMed     Abstract available
    
    
    August 2022
16. MANKOFF DA, Clark AS, Edmonds CE, O'Brien SR, et al
    16alpha-[(18)F]Fluoro-17beta-Estradiol Positron Emission Tomography to Measure Regional Estrogen Receptor Expression in Breast Cancer.
    J Clin Oncol. 2022 Aug 30:JCO2201055. doi: 10.1200/JCO.22.01055.
    PubMed    
    
    
    
17. RUGO HS, Bardia A, Marme F, Cortes J, et al
    Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
    J Clin Oncol. 2022 Aug 26:JCO2201002. doi: 10.1200/JCO.22.01002.
    PubMed     Abstract available
    
    
    
18. DAVIDSON NE
    In It for the Long Haul: Long-Term Benefit With Adjuvant Endocrine Therapy for Premenopausal Women With Early-Stage Steroid Receptor-Positive Breast Cancer.
    J Clin Oncol. 2022 Aug 26:JCO2201465. doi: 10.1200/JCO.22.01465.
    PubMed    
    
    
    
19. OFFERSEN BV, Alsner J, Nielsen HM, Jakobsen EH, et al
    Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial.
    J Clin Oncol. 2022 Aug 5:JCO2200451. doi: 10.1200/JCO.22.00451.
    PubMed     Abstract available
    
    
    
20. MOY B, Rumble RB, Carey LA
    Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2022 Aug 4:JCO2201533. doi: 10.1200/JCO.22.01533.
    PubMed     Abstract available
    
    
    July 2022
21. JOHANSSON A, Dar H, van 't Veer LJ, Tobin NP, et al
    Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.
    J Clin Oncol. 2022 Jul 21:JCO2102844. doi: 10.1200/JCO.21.02844.
    PubMed     Abstract available
    
    
    
22. RUGO HS, Umanzor GA, Barrios FJ, Vasallo RH, et al
    Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer.
    J Clin Oncol. 2022 Jul 20:JCO2102953. doi: 10.1200/JCO.21.02953.
    PubMed     Abstract available
    
    
    
23. ULAS KAHYA B, Sutcuoglu O, Yazici O, Ozdemir N, et al
    Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).
    J Clin Oncol. 2022 Jul 12:JCO2200404. doi: 10.1200/JCO.22.00404.
    PubMed    
    
    
    
24. SORAN A, Aytac O, Ozbas S
    Locoregional Therapy for Intact Primary Tumor in De Novo Stage IV Breast Cancer.
    J Clin Oncol. 2022 Jul 12:JCO2200802. doi: 10.1200/JCO.22.00802.
    PubMed    
    
    
    
25. LU Y, Meng D, Hui B, Yuan W, et al
    The Deep Inspiration Breath-Hold Technique May Be a Win-Win Option for the Treatment of Patients in Node-Positive Early Left-Sided Breast Cancer.
    J Clin Oncol. 2022 Jul 5:JCO2200931. doi: 10.1200/JCO.22.00931.
    PubMed    
    
    
    June 2022
26. COBAIN EF, Hayes DF
    Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
    J Clin Oncol. 2022 Jun 29:JCO2200702. doi: 10.1200/JCO.22.00702.
    PubMed    
    
    
    
27. HUOBER J, Barrios CH, Niikura N, Jarzab M, et al
    Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.
    J Clin Oncol. 2022 Jun 28:JCO2102772. doi: 10.1200/JCO.21.02772.
    PubMed     Abstract available
    
    
    
28. HENRY NL, Somerfield MR, Dayao Z, Elias A, et al
    Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update.
    J Clin Oncol. 2022 Jun 27:JCO2201063. doi: 10.1200/JCO.22.01063.
    PubMed     Abstract available
    
    
    
29. CHEN YJ, Yeh MH, Wei JC
    Considerations of Subgroup Classification When Analyzing Risk of Developing Cardiometabolic Risk Factors in Patients With Breast Cancer.
    J Clin Oncol. 2022 Jun 16:JCO2200416. doi: 10.1200/JCO.22.00416.
    PubMed    
    
    
    
30. PHILLIPS KA, Friedlander ML
    Risk of Peritoneal Cancer After Risk-Reducing Bilateral Salpingo-Oophorectomy for Women With Germline BRCA Pathogenic Variants: A Cause for Concern or Potentially Avoidable?
    J Clin Oncol. 2022;40:1850-1852.
    PubMed    
    
    
    
31. STEENBEEK MP, van Bommel MHD, Bulten J, Hulsmann JA, et al
    Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis.
    J Clin Oncol. 2022;40:1879-1891.
    PubMed     Abstract available
    
    
    
32. REDING KW, Cheng RK, Barac A, Vasbinder A, et al
    Toward a Better Understanding of the Differential Impact of Heart Failure Phenotypes After Breast Cancer.
    J Clin Oncol. 2022 Jun 10:JCO2200111. doi: 10.1200/JCO.22.00111.
    PubMed    
    
    
    
33. MITTENDORF EA, King TA, Tolaney SM
    Impact of RxPONDER and monarchE on the Surgical Management of the Axilla in Patients With Breast Cancer.
    J Clin Oncol. 2022 Jun 8:JCO2200173. doi: 10.1200/JCO.22.00173.
    PubMed    
    
    
    
34. CESCON DW, Kalinsky K, DeMichele AM
    Can a Late Interception by Circulating Tumor DNA Deliver a Win in Estrogen Receptor-Positive Early Breast Cancer?
    J Clin Oncol. 2022 Jun 4:JCO2201026. doi: 10.1200/JCO.22.01026.
    PubMed    
    
    
    
35. LIPSYC-SHARF M, de Bruin EC, Santos K, McEwen R, et al
    Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
    J Clin Oncol. 2022 Jun 4:JCO2200908. doi: 10.1200/JCO.22.00908.
    PubMed     Abstract available
    
    
    
36. BROOKS GA, Landrum MB, Kapadia NS, Liu PH, et al
    Impact of the Oncology Care Model on Use of Supportive Care Medications During Cancer Treatment.
    J Clin Oncol. 2022;40:1763-1771.
    PubMed     Abstract available
    
    
    
37. ZACHARAKIS N, Huq LM, Seitter SJ, Kim SP, et al
    Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes.
    J Clin Oncol. 2022;40:1741-1754.
    PubMed     Abstract available
    
    
    May 2022
38. GIORDANO SH, Franzoi MAB, Temin S, Anders CK, et al
    Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update.
    J Clin Oncol. 2022 May 31:JCO2200519. doi: 10.1200/JCO.22.00519.
    PubMed     Abstract available
    
    
    
39. RAMAKRISHNA N, Anders CK, Lin NU, Morikawa A, et al
    Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update.
    J Clin Oncol. 2022 May 31:JCO2200520. doi: 10.1200/JCO.22.00520.
    PubMed     Abstract available
    
    
    
40. BACHELOT T, Cottu P, Chabaud S, Dalenc F, et al
    Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
    J Clin Oncol. 2022 May 23:JCO2102179. doi: 10.1200/JCO.21.02179.
    PubMed     Abstract available
    
    
    
41. VAN GEEL JJL, Boers J, Elias SG, Glaudemans AWJM, et al
    Clinical Validity of 16alpha-[(18)F]Fluoro-17beta-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer.
    J Clin Oncol. 2022 May 18:JCO2200400. doi: 10.1200/JCO.22.00400.
    PubMed     Abstract available
    
    
    
42. BIDARD FC, Kaklamani VG, Neven P, Streich G, et al
    Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
    J Clin Oncol. 2022 May 18:JCO2200338. doi: 10.1200/JCO.22.00338.
    PubMed     Abstract available
    
    
    
43. FALLET V, Sanchis-Borja M, Benusiglio PR, Cadranel J, et al
    Do Female BRCA2 Pathogenic Variant Carriers Have an Increased Risk of Lung Cancer?
    J Clin Oncol. 2022 May 12:JCO2200488. doi: 10.1200/JCO.22.00488.
    PubMed    
    
    
    
44. LIEBERMAN S, Goldvaser H, Levy-Lahad E
    Germline Pathogenic Variants in BRCA1 and BRCA2: Malignancies Beyond Female Breast and Ovarian Cancers.
    J Clin Oncol. 2022;40:1590-1594.
    PubMed    
    
    
    
45. DAMODARAN S, Zhao F, Deming DA, Mitchell EP, et al
    Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.
    J Clin Oncol. 2022;40:1552-1561.
    PubMed     Abstract available
    
    
    
46. LI S, Silvestri V, Leslie G, Rebbeck TR, et al
    Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants.
    J Clin Oncol. 2022;40:1529-1541.
    PubMed     Abstract available
    
    
    
47. SINGLETON AC, Raeside R, Hyun KK, Partridge SR, et al
    Electronic Health Interventions for Patients With Breast Cancer: Systematic Review and Meta-Analyses.
    J Clin Oncol. 2022 May 2:JCO2101171. doi: 10.1200/JCO.21.01171.
    PubMed     Abstract available
    
    
    April 2022
48. JIN Z, Zhang S, Zhang L, Chen Q, et al
    Artificial Intelligence Risk Model (Mirai) Delivers Robust Generalization and Outperforms Tyrer-Cuzick Guidelines in Breast Cancer Screening.
    J Clin Oncol. 2022 Apr 22:JCO2102908. doi: 10.1200/JCO.21.02908.
    PubMed    
    
    
    
49. ERIKSSON M, Conant EF, Kontos D, Hall P, et al
    Risk Assessment in Population-Based Breast Cancer Screening.
    J Clin Oncol. 2022 Apr 22:JCO2102827. doi: 10.1200/JCO.21.02827.
    PubMed    
    
    
    
50. DI MEGLIO A, Havas J, Gbenou AS, Martin E, et al
    Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy.
    J Clin Oncol. 2022 Apr 21:JCO2100277. doi: 10.1200/JCO.21.00277.
    PubMed     Abstract available
    
    
    
51. VLIEK SB, Noordhoek I, Meershoek-Klein Kranenbarg E, van Rossum AGJ, et al
    Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial.
    J Clin Oncol. 2022 Apr 20:JCO2100311. doi: 10.1200/JCO.21.00311.
    PubMed     Abstract available
    
    
    
52. LOPES CARDOZO JMN, Drukker CA, Rutgers EJT, Schmidt MK, et al
    Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial.
    J Clin Oncol. 2022;40:1335-1345.
    PubMed     Abstract available
    
    
    
53. BEAVIS PA, Derrick EB, Loi S
    Challenges of Creating New Tumor-Infiltrating Lymphocyte for Combating Breast Cancer.
    J Clin Oncol. 2022 Apr 19:JCO2200284. doi: 10.1200/JCO.22.00284.
    PubMed    
    
    
    
54. BRAUER ER, Ganz PA
    Moving the Translational Needle in Breast Cancer Survivorship: Connecting Intervention Research to Clinical Practice.
    J Clin Oncol. 2022 Apr 19:JCO2200174. doi: 10.1200/JCO.22.00174.
    PubMed    
    
    
    
55. ANDRE F, Ismaila N, Allison KH, Barlow WE, et al
    Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.
    J Clin Oncol. 2022 Apr 19:JCO2200069. doi: 10.1200/JCO.22.00069.
    PubMed     Abstract available
    
    
    
56. ASAZUMA K, Shimomura A, Shimizu C
    Antibody-Drug Conjugates as an Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
    J Clin Oncol. 2022 Apr 14:JCO2200135. doi: 10.1200/JCO.22.00135.
    PubMed    
    
    
    
57. KORDE LA, Somerfield MR, Hershman DL
    Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2022 Apr 13:JCO2200503. doi: 10.1200/JCO.22.00503.
    PubMed     Abstract available
    
    
    
58. DOWSETT M
    Testing Endocrine Response for Managing Primary Estrogen Receptor-Positive Breast Cancer.
    J Clin Oncol. 2022 Apr 12:JCO2200214. doi: 10.1200/JCO.22.00214.
    PubMed    
    
    
    
59. NITZ UA, Gluz O, Kummel S, Christgen M, et al
    Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer.
    J Clin Oncol. 2022 Apr 11:JCO2102759. doi: 10.1200/JCO.21.02759.
    PubMed     Abstract available
    
    
    
60. THORSEN LBJ, Overgaard J, Matthiessen LW, Berg M, et al
    Internal Mammary Node Irradiation in Patients With Node-Positive Early Breast Cancer: Fifteen-Year Results From the Danish Breast Cancer Group Internal Mammary Node Study.
    J Clin Oncol. 2022 Apr 8:JCO2200044. doi: 10.1200/JCO.22.00044.
    PubMed     Abstract available
    
    
    
61. GREENLEE H, Iribarren C, Rana JS, Cheng R, et al
    Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study.
    J Clin Oncol. 2022 Apr 6:JCO2101736. doi: 10.1200/JCO.21.01736.
    PubMed     Abstract available
    
    
    March 2022
62. NOZAWA K, Hattori M, Yoshimura A, Iwata H, et al
    Clinical Utility of Precision Medicine in Early Breast Cancer: What Is the Optimal Framework to Develop Precision Medicine?
    J Clin Oncol. 2022 Mar 31:JCO2200153. doi: 10.1200/JCO.22.00153.
    PubMed    
    
    
    
63. DE JONG VMT, Wang Y, Ter Hoeve ND, Opdam M, et al
    Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.
    J Clin Oncol. 2022 Mar 30:JCO2101536. doi: 10.1200/JCO.21.01536.
    PubMed     Abstract available
    
    
    
64. QIN B, Kim K, Goldman N, Rundle AG, et al
    Multilevel Factors for Adiposity Change in a Population-Based Prospective Study of Black Breast Cancer Survivors.
    J Clin Oncol. 2022 Mar 25:JCO2102973. doi: 10.1200/JCO.21.02973.
    PubMed     Abstract available
    
    
    
65. VAZ-LUIS I, Di Meglio A, Havas J, El-Mouhebb M, et al
    Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis.
    J Clin Oncol. 2022 Mar 15:JCO2101958. doi: 10.1200/JCO.21.01958.
    PubMed     Abstract available
    
    
    
66. SALERNO EA, Culakova E, Heckler CE, Janelsins MC, et al
    Reply to S. Ning et al.
    J Clin Oncol. 2022;40:916-918.
    PubMed    
    
    
    
67. DELAHUNTY R, Nguyen L, Craig S, Creighton B, et al
    TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.
    J Clin Oncol. 2022 Mar 9:JCO2102108. doi: 10.1200/JCO.21.02108.
    PubMed     Abstract available
    
    
    
68. JATOI I
    Ductal Carcinoma In Situ and Breast Cancer Overdiagnosis.
    J Clin Oncol. 2022 Mar 4:JCO2102802. doi: 10.1200/JCO.21.02802.
    PubMed    
    
    
    
69. GRIMM LJ, Plichta JK, Hwang ES
    More Than Incremental: Harnessing Machine Learning to Predict Breast Cancer Risk.
    J Clin Oncol. 2022 Mar 4:JCO2102733. doi: 10.1200/JCO.21.02733.
    PubMed    
    
    
    
70. THOMAS A, Parsons HA, Smith KL
    Late Recurrence Following Early Breast Cancer.
    J Clin Oncol. 2022 Mar 3:JCO2200167. doi: 10.1200/JCO.22.00167.
    PubMed     Abstract available
    
    
    February 2022
71. JAHAN N, Cathcart-Rake EJ, Ruddy KJ
    Late Breast Cancer Survivorship: Side Effects and Care Recommendations.
    J Clin Oncol. 2022 Feb 28:JCO2200049. doi: 10.1200/JCO.22.00049.
    PubMed     Abstract available
    
    
    
72. HICKS D, O'Regan RM
    Improving Outcomes for High-Risk Hormone Receptor-Positive Breast Cancer With CDK Inhibition.
    J Clin Oncol. 2022 Feb 24:JCO2102850. doi: 10.1200/JCO.21.02850.
    PubMed     Abstract available
    
    
    
73. KEMP EB, Geerse OP, Knowles R, Woodman R, et al
    Mapping Systematic Reviews of Breast Cancer Survivorship Interventions: A Network Analysis.
    J Clin Oncol. 2022 Feb 16:JCO2102015. doi: 10.1200/JCO.21.02015.
    PubMed     Abstract available
    
    
    
74. PEDERSEN RN, Mellemkjaer L, Ejlertsen B, Norgaard M, et al
    Mortality After Late Breast Cancer Recurrence in Denmark.
    J Clin Oncol. 2022 Feb 16:JCO2102062. doi: 10.1200/JCO.21.02062.
    PubMed     Abstract available
    
    
    
75. ANG BH, Ho WK, Wijaya E, Kwan PY, et al
    Predicting the Likelihood of Carrying a BRCA1 or BRCA2 Mutation in Asian Patients With Breast Cancer.
    J Clin Oncol. 2022 Feb 10:JCO2101647. doi: 10.1200/JCO.21.01647.
    PubMed     Abstract available
    
    
    
76. ANDERSON DN, Port ER
    Surgery No More? Managing the Primary Tumor in Stage IV Breast Cancer.
    J Clin Oncol. 2022 Feb 4:JCO2102706. doi: 10.1200/JCO.21.02706.
    PubMed     Abstract available
    
    
    
77. PARAMANANDAM VS, Dylke E, Clark GM, Daptardar AA, et al
    Prophylactic Use of Compression Sleeves Reduces the Incidence of Arm Swelling in Women at High Risk of Breast Cancer-Related Lymphedema: A Randomized Controlled Trial.
    J Clin Oncol. 2022 Feb 2:JCO2102567. doi: 10.1200/JCO.21.02567.
    PubMed     Abstract available
    
    
    
78. PFOB A, Sidey-Gibbons C, Rauch G, Thomas B, et al
    Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery.
    J Clin Oncol. 2022 Feb 2:JCO2102439. doi: 10.1200/JCO.21.02439.
    PubMed     Abstract available
    
    
    
79. CARLOS RC, Obeng-Gyasi S, Cole SW, Zebrack BJ, et al
    Linking Structural Racism and Discrimination and Breast Cancer Outcomes: A Social Genomics Approach.
    J Clin Oncol. 2022 Feb 2:JCO2102004. doi: 10.1200/JCO.21.02004.
    PubMed    
    
    
    
80. BARTON DL, Pugh SL, Ganz PA, Plaxe SC, et al
    Randomized Controlled Phase II Evaluation of Two Dose Levels of Bupropion Versus Placebo for Sexual Desire in Female Cancer Survivors: NRG-CC004.
    J Clin Oncol. 2022;40:324-334.
    PubMed     Abstract available
    
    
    January 2022
81. ROYCE M, Osgood C, Mulkey F, Bloomquist E, et al
    FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer.
    J Clin Oncol. 2022 Jan 27:JCO2102742. doi: 10.1200/JCO.21.02742.
    PubMed     Abstract available
    
    
    
82. RAFN BS, Christensen J, Larsen A, Bloomquist K, et al
    Prospective Surveillance for Breast Cancer-Related Arm Lymphedema: A Systematic Review and Meta-Analysis.
    J Clin Oncol. 2022 Jan 25:JCO2101681. doi: 10.1200/JCO.21.01681.
    PubMed     Abstract available
    
    
    
83. DI MEGLIO A, Havas J, Soldato D, Presti D, et al
    Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care.
    J Clin Oncol. 2022 Jan 21:JCO2101252. doi: 10.1200/JCO.21.01252.
    PubMed     Abstract available
    
    
    
84. NING S, Qiao K, Pan L
    Physical Activity Patterns and Cognitive Function in Patients With Breast Cancer.
    J Clin Oncol. 2022 Jan 21:JCO2102073. doi: 10.1200/JCO.21.02073.
    PubMed    
    
    
    
85. WRIGHT JL, Rahbar H, Obeng-Gyasi S, Carlos R, et al
    Overcoming Barriers in Ductal Carcinoma In Situ Management: From Overtreatment to Optimal Treatment.
    J Clin Oncol. 2022;40:225-230.
    PubMed    
    
    
    
86. SHEPHERD JH, Ballman K, Polley MC, Campbell JD, et al
    CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
    J Clin Oncol. 2022 Jan 19:JCO2101506. doi: 10.1200/JCO.21.01506.
    PubMed     Abstract available
    
    
    
87. EISEN A, Somerfield MR, Accordino MK, Blanchette PS, et al
    Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.
    J Clin Oncol. 2022 Jan 18:JCO2102647. doi: 10.1200/JCO.21.02647.
    PubMed     Abstract available
    
    
    
88. KWAN ML, Cheng RK, Iribarren C, Neugebauer R, et al
    Risk of Cardiometabolic Risk Factors in Women With and Without a History of Breast Cancer: The Pathways Heart Study.
    J Clin Oncol. 2022 Jan 13:JCO2101738. doi: 10.1200/JCO.21.01738.
    PubMed     Abstract available
    
    
    
89. JOENSUU H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola A, et al
    Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial.
    J Clin Oncol. 2022 Jan 12:JCO2102054. doi: 10.1200/JCO.21.02054.
    PubMed     Abstract available
    
    
    
90. KHAN SA, Zhao F, Goldstein LJ, Cella D, et al
    Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).
    J Clin Oncol. 2022 Jan 7:JCO2102006. doi: 10.1200/JCO.21.02006.
    PubMed     Abstract available
    
    
    
91. MAYER EL, Fesl C, Hlauschek D, Garcia-Estevez L, et al
    Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/AB
    J Clin Oncol. 2022 Jan 7:JCO2101918. doi: 10.1200/JCO.21.01918.
    PubMed     Abstract available
    
    
    December 2021
92. SCHNEIDER BP, Jiang G, Ballinger TJ, Shen F, et al
    BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.
    J Clin Oncol. 2021 Dec 15:JCO2101657. doi: 10.1200/JCO.21.01657.
    PubMed     Abstract available
    
    
    
93. KROP IE, Im SA, Barrios C, Bonnefoi H, et al
    Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.
    J Clin Oncol. 2021 Dec 10:JCO2100896. doi: 10.1200/JCO.21.00896.
    PubMed     Abstract available
    
    
    
94. YADAV S, Hu C, Nathanson KL, Weitzel JN, et al
    Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast.
    J Clin Oncol. 2021;39:3918-3926.
    PubMed     Abstract available
    
    
    
95. GIORDANO SH, Freedman RA, Somerfield MR
    Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.
    J Clin Oncol. 2021 Dec 8:JCO2102677. doi: 10.1200/JCO.21.02677.
    PubMed     Abstract available
    
    
    
96. GNANT M, Dueck AC, Frantal S, Martin M, et al
    Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
    J Clin Oncol. 2021 Dec 7:JCO2102554. doi: 10.1200/JCO.21.02554.
    PubMed     Abstract available
    
    
    November 2021
97. YALA A, Mikhael PG, Strand F, Lin G, et al
    Multi-Institutional Validation of a Mammography-Based Breast Cancer Risk Model.
    J Clin Oncol. 2021 Nov 12:JCO2101337. doi: 10.1200/JCO.21.01337.
    PubMed     Abstract available
    
    
    
98. WARREN LEG, Bellon JR
    Should Everyone With Ductal Carcinoma in Situ Receive Adjuvant Radiation?
    J Clin Oncol. 2021;39:3535-3540.
    PubMed     Abstract available
    
    
    
99. MCCORMICK B, Winter KA, Woodward W, Kuerer HM, et al
    Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804.
    J Clin Oncol. 2021;39:3574-3582.
    PubMed     Abstract available
    
    
    October 2021
100. BORGES VF
     Options for Endocrine-Refractory, Hormone Receptor-Positive Breast Cancer: Which Target and When?
     J Clin Oncol. 2021 Oct 28:JCO2101910. doi: 10.1200/JCO.21.01910.
     PubMed     Abstract available
     
     
     
101. ADEMUYIWA FO, Salyer P, Tao Y, Luo J, et al
     Genetic Counseling and Testing in African American Patients With Breast Cancer: A Nationwide Survey of US Breast Oncologists.
     J Clin Oncol. 2021 Oct 18:JCO2101426. doi: 10.1200/JCO.21.01426.
     PubMed     Abstract available
     
     
     
102. PALMER JR, Zirpoli G, Bertrand KA, Battaglia T, et al
     A Validated Risk Prediction Model for Breast Cancer in US Black Women.
     J Clin Oncol. 2021 Oct 8:JCO2101236. doi: 10.1200/JCO.21.01236.
     PubMed     Abstract available
     
     
     September 2021
103. DE RUITER MB, Reneman L, Kieffer JM, Oldenburg HSA, et al
     Brain White Matter Microstructure as a Risk Factor for Cognitive Decline After Chemotherapy for Breast Cancer.
     J Clin Oncol. 2021 Sep 30:JCO2100627. doi: 10.1200/JCO.21.00627.
     PubMed     Abstract available
     
     
     
104. JAYASEKERA J, Sparano JA, O'Neill S, Chandler Y, et al
     Development and Validation of a Simulation Model-Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions.
     J Clin Oncol. 2021;39:2893-2902.
     PubMed     Abstract available
     
     
     July 2021
105. COBLEIGH MA, Anderson SJ, Siziopikou KP, Arthur DW, et al
     Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial.
     J Clin Oncol. 2021;39:2367-2374.
     PubMed     Abstract available
     
     
     June 2021
106. TURAN V, Lambertini M, Lee DY, Wang E, et al
     Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data.
     J Clin Oncol. 2021;39:2016-2024.
     PubMed     Abstract available
     
     
     
107. ERIKSSON M, Eklund M, Borgquist S, Hellgren R, et al
     Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.
     J Clin Oncol. 2021;39:1899-1908.
     PubMed     Abstract available
     
     
     May 2021
108. PRAT A, Chaudhury A, Solovieff N, Pare L, et al
     Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies.
     J Clin Oncol. 2021;39:1458-1467.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: